Downstream of BMPR2, non-canonical transcription factors (TFs) can be pharmacologically harnessed to reverse experimental PH (28, 32–35) and repair prevalent DNA damage in PAEC from PAH patients harboring BMPR2 mutations (28) uncovering an additional BMPR2-dependent disease-modifying approach. The gene discussed is BMPR2; the disease is pulmonary arterial hypertension.